The role of corticosteroids in Duchenne muscular dystrophy: a review for the anesthetist
2005; Wiley; Volume: 15; Issue: 1 Linguagem: Inglês
10.1111/j.1460-9592.2005.01424.x
ISSN1460-9592
AutoresWarwick A. Ames, Jason Hayes, Mark W. Crawford,
Tópico(s)Neurogenetic and Muscular Disorders Research
ResumoPediatric AnesthesiaVolume 15, Issue 1 p. 3-8 The role of corticosteroids in Duchenne muscular dystrophy: a review for the anesthetist WARWICK A. AMES MBBS FRCA, WARWICK A. AMES MBBS FRCA Department of Anesthesia, The Hospital for Sick Children, Toronto, Ontario, CanadaSearch for more papers by this authorJASON A. HAYES MD FRCPC, JASON A. HAYES MD FRCPC Department of Anesthesia, The Hospital for Sick Children, Toronto, Ontario, CanadaSearch for more papers by this authorMARK W. CRAWFORD MBBS FRCPC, MARK W. CRAWFORD MBBS FRCPC Department of Anesthesia, The Hospital for Sick Children, Toronto, Ontario, CanadaSearch for more papers by this author WARWICK A. AMES MBBS FRCA, WARWICK A. AMES MBBS FRCA Department of Anesthesia, The Hospital for Sick Children, Toronto, Ontario, CanadaSearch for more papers by this authorJASON A. HAYES MD FRCPC, JASON A. HAYES MD FRCPC Department of Anesthesia, The Hospital for Sick Children, Toronto, Ontario, CanadaSearch for more papers by this authorMARK W. CRAWFORD MBBS FRCPC, MARK W. CRAWFORD MBBS FRCPC Department of Anesthesia, The Hospital for Sick Children, Toronto, Ontario, CanadaSearch for more papers by this author First published: 11 January 2005 https://doi.org/10.1111/j.1460-9592.2005.01424.xCitations: 20 Dr Warwick A. Ames, Department of Anesthesia, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada (email: [email protected]). Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Morris P. Duchenne muscular dystrophy: a challenge for the anaesthetist. Pediatr Anesth 1997; 7: 1– 4. 2 Sethna NF, Rockoff MA, Worthen HM et al. Anesthesia-related complications in children with Duchenne muscular dystrophy. Anesthesiology 1988; 68: 462– 465. 3 Kerr TP, Durward A, Hodgson SV et al. Hyperkalaemic cardiac arrest in a manifesting carrier of Duchenne muscular dystrophy following general anaesthesia. Eur J Pediatr 2001; 160: 579– 580. 4 Weimann RL, Gibson DA, Moseley CV. Surgical stabilization of the spine in Duchenne muscular dystrophy. Spine 1983; 8: 776– 780. 5 Hahn A, Bach JR, Delaubier A et al. Clinical implications of maximal respiratory pressure determinations for individuals with Duchenne muscular dystrophy. Arch Phys Med Rehabil 1997; 78: 1– 6. 6 Emery AEH. Duchenne Muscular Dystrophy, 2nd edn. Oxford: Oxford University Press, 1993: 277. 7 Benson ER, Thomson JD, Smith BG et al. Results and morbidity in a consecutive series of patients undergoing spinal fusion for neuromuscular scoliosis. Spine 1998; 23: 2308– 2318. 8 Ramirez N, Richards BS, Warren PD et al. Complications after posterior spinal fusion in Duchenne's muscular dystrophy. J Pediatr Orthop 1997; 17: 109– 114. 9 Miller F, Moseley CF, Koreska J. Spinal fusion in Duchenne muscular dystrophy. Dev Med Child Neurol 1992; 34: 775– 786. 10 Jenkins JG, Bohn D, Edmonds JF et al. Evaluation of pulmonmary function in muscular dystrophy patients requiring spinal surgery. Crit Care Med 1982; 10: 645– 649. 11 Perloff JK, Roberts WC, de Leon AC et al. The distinctive electrocardiogram of Duchenne's progressive muscular dystrophy. An electrocardiographic-pathologic correlative study. Am J Med 1967; 42: 179– 188. 12 Ramaciotti C, Iannaccone ST, Scott WA. Myocardial cell damage in Duchenne muscular dystrophy. Pediatr Cardiol 2003; 24: 503– 506. 13 Silversides CK, Webb GD, Harris VA et al. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 2003; 91: 769– 772. 14 Annane D, Merlet P, Radvanyi H et al. Blunted coronary reserve in myotonic dystrophy. An early and gene-related phenomenon. Circulation 1996; 94: 973– 977. 15 Gnecchi-Ruscone T, Taylor J, Mercuri E et al. Cardiomyopathy in Duchenne, Becker, and sarcoglycanopathies: a role for coronary dysfunction? Muscle Nerve 1999; 22: 1549– 1556. 16 Sander M, Chavoshan B, Harris SA et al. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2000; 97: 13818– 13823. 17 Schmidt GN, Burmeister MA, Lilje C et al. Acute heart failure during spinal surgery in a boy with Duchenne muscular dystrophy. Br J Anaesth 2003; 90: 800– 804. 18 Wong BLY, Christopher C. Corticosteroids in Duchenne muscular dystrophy: a reappraisal. J Child Neurol 2002; 17: 183– 190. 19 Brooke MH, Fenichel GM, Griggs RC et al. Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone. Arch Neurol 1987; 44: 812– 827. 20 Mendell JR, Moxley RT, Griggs RC et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989; 320: 1592– 1597. 21 Griggs RC, Moxley RT, Mendell JR et al. Prednisone in Duchenne dystrophy. Arch Neurol 1991; 48: 383– 388. 22 Fenichel GM, Mendell JR, Moxley RT et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 1991; 48: 575– 579. 23 Fenichel GM, Florence JM, Pestronk A et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991; 41: 1874– 1877. 24 Griggs RC, Moxley RT, Mendell MD et al. Duchenne dystrophy: Randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993; 43: 520– 527. 25 Sansome A, Royston P, Dubowitz V. Steroids in Duchenne muscular dystrophy: pilot study of a new low-dosage schedule. Neuromusc Disord 1993; 3: 567– 569. 26 Mesa LE, Dubrovsky AL, Corderi J et al. Steroids in Duchenne muscular dystrophy – deflazacort trial. Neuromusc Disord 1991; 1: 261– 266. 27 Angelini C, Pegoraro E, Turella E et al. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve 1994; 17: 386– 391. 28 Reitter B. Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain Dev 1995; 17 (Suppl.): 39– 43. 29 Bonifati MD, Ruzza G, Bonometto P et al. A multicenter, double-blind, randomized trial of deflazacort vs prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000; 23: 1344– 1347. 30 Biggar WD, Gingras M, Feblings DL et al. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 2001; 138: 45– 50. 31 Fenichel G, Pestronk A, Florence J et al. A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study. Neurology 1997; 48: 1225– 1226. 32 Fenichel GM, Griggs RC, Kissel J et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology 2001; 56: 1075– 1079. 33 Kawai H, Adachi K, Nishida Y et al. Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne muscular dystrophy during glucocorticoid treatment. J Neurol 1193; 240: 181– 186. 34 Rifai Z, Moxley RT, Lorenson M et al. Effect of prednisone on growth hormone and insulin-like growth factor I in Duchenne dystrophy. Neurology 1993; 43 (Suppl.): A202. 35 Leijendekker WJ, Passaquin AC, Metzinger L et al. Regulation of cytosolic calcium in skeletal muscle cells of the mdx mouse under conditions of stress. Br J Pharmacol 1996; 118: 611– 616. 36 Passaquin AC, Metzinger L, Léger JJ et al. Prednisolone enhances myogenesis and dystrophin-related protein in skeletal muscle cell cultures from mdx mice. J Neurosci Res 1993; 35: 363– 372. 37 Anderson JE, McIntosh LM, Poettcker R. Deflazacort but not prednisone improves both muscle repair and fiber growth in diaphragm and limb muscle in vivo in the mdx dystrophic mouse. Muscle Nerve 1996; 19: 1576– 1585. 38 Rifai Z, Welle S, Moxley RT et al. Effect of prednisone on protein metabolism in Duchenne dystrophy. Am J Physiol 1995; 268: E67– E74. 39 Drachman DB, Toyka KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet 1974; 2: 1409– 1412. 40 Siegel IM, Miller JE, Ray RD. Failure of corticosteroid in the treatment of Duchenne (pseudohypertrophic) muscular dystrophy: Report of a clinically matched three year double-blind study. Ill Med J 1974; 145: 32– 36. 41 DeSilva S, Drachman DB, Mellitis D et al. Prednisone treatment in Duchenne muscular dystrophy: long-term benefit. Arch Neurol 1987; 44: 818– 822. 42 Bäckman E, Henriksson KG. Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromusc Disord 1995; 3: 233– 241. 43 Dubowitz V, Kinali M, Muntoni F. Clinical remission in early Duchenne dystrophy on intermittent prednisolone therapy, abstract. Neuromusc Disorder 2000; 10: 351– 352. 44 Carter GT, McDonald CM. Preserving function in Duchenne dystrophy with long-term pulse prednisone therapy. Am J Phys Med Rehabil 2000; 79: 455– 458. 45 Kinali M, Mercuri E, Main M et al. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromuscl Disord 2002; 12 (Suppl. 1): S169– S174. 46 Connolly AM, Shierbecker J, Renna R et al. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2002; 12: 917– 925. 47 Alman BA, Raza SN, Biggar WD. Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy. J Bone Joint Surg Am 2004; 86-A: 519– 524. 48 Rosenfeld RG, Frane J, Attie KM et al. Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome. J Pediatr 1992; 121: 49– 55. 49 Albanese A, Kewley GD, Long A et al. Oral treatment for constitutional delay of growth and puberty in boys: a randomised trial of an anabolic steroid or testosterone undecanoate. Arch Dis Child 1994; 71: 315– 317. 50 Wilson DM, McCauley E, Brown DR et al. Oxandrolone therapy in constitutionally delayed growth and puberty. Bio-Technology General Corporation Cooperative Study Group. Pediatrics 1995; 96: 1095– 1100. 51 Merlini L, Cicognani A, Malaspina E et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve 2003; 27: 222– 227. 52 Bothwell JE, Gordon KE, Dooley JM et al. Vertebral fractures in boys with Duchenne muscular dystrophy. Clin Pediatr 2003; 42: 353– 356. 53 Dubowitz V. 75th European Neuromuscular Centre International Workshop: 2nd workshop on the treatment of muscular dystrophy, 10–12 December 1999, Naarden, The Netherlands. Neuromusc Disord 2000; 10: 313– 320. 54 Larach MG, Rosenberg H, Gronert GA et al. Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies. Clin Pediatr (Phila) 1997; 36: 9– 16. 55 Goresky GV, Cox RG. Inhalation anesthetics and Duchenne's muscular dystrophy. Can J Anaesth 1999; 46: 525– 528. 56 Hayes JA, Ames WA. Acute heart failure during spinal surgery in a boy with Duchenne muscular dystrophy. Br J Anaesth 2004; 92: 149. 57 Brownell AKW. Malignant hyperthermia: relationship to other diseases. BJA 1988; 60: 303– 308. 58 Brown JC, Charlton JE, White DJK. A regional technique for the study of sensitivity to curare in human muscle. J Neurol Neurosurg Psych 1975; 38: 18– 26. 59 Jacobs SC, Bootsma AL, Willems PW et al. Prednisone can protect against exercise-induced muscle damage. J Neurol 1996; 243: 410– 416. 60 Nicholson G, Burrin JM, Hall GM. Peri-operative steroid supplementation. Anaesthesia 1998; 53: 1091– 1104. Citing Literature Volume15, Issue1January 2005Pages 3-8 ReferencesRelatedInformation
Referência(s)